跳转至内容
Merck

1046205

USP

氨曲南

United States Pharmacopeia (USP) Reference Standard

别名:

[2S-[2α,3β(Z)]]-2-[[[1-(2-氨基-4-噻唑基)-2-[(2-甲基-4-氧代-1-磺基-3-氮杂环丁烷)氨基]-2-氧代亚乙基]氨基]氧代]-2-甲基丙酸

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C13H17N5O8S2
CAS号:
分子量:
435.43
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

aztreonam

制造商/商品名称

USP

应用

pharmaceutical (small molecule)

包装形式

neat

储存温度

−20°C

SMILES字符串

C[C@H]1[C@H](NC(=O)\C(=N/OC(C)(C)C(O)=O)c2csc(N)n2)C(=O)N1S(O)(=O)=O

InChI

1S/C13H17N5O8S2/c1-5-7(10(20)18(5)28(23,24)25)16-9(19)8(6-4-27-12(14)15-6)17-26-13(2,3)11(21)22/h4-5,7H,1-3H3,(H2,14,15)(H,16,19)(H,21,22)(H,23,24,25)/b17-8-/t5-,7-/m0/s1

InChI key

WZPBZJONDBGPKJ-VEHQQRBSSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Aztreonam USP reference standard is meant to use for specified quality tests and assays.

Also used to prepare standard and system suitability solutions for assay according to the given below monographs of United States Pharmacopeia (USP):
  • Aztreonam
  • Aztreonam for Injection
  • Aztreonam Injection

分析说明

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他说明

Sales restrictions may apply.

储存分类代码

11 - Combustible Solids

WGK

WGK 2

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Aztreonam for Injection
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 39(3), 463-463 (2018)
Aztreonam Injection
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 39(3), 462-462 (2018)
Michael N Dudley et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 56(9), 1301-1309 (2013-01-22)
Widespread resistance in Enterobacteriaceae and Pseudomonas aeruginosa to cephalosporin and monobactam antibiotics due to extended-spectrum β-lactamases (ESBLs) has resulted in the need for reassessment of the interpretative criteria (breakpoints) established for these agents more than 2 decades ago. Following extensive
H Mattie
Clinical pharmacokinetics, 26(2), 99-106 (1994-02-01)
Plasma concentrations of aztreonam follow a 2-compartment open model with a distribution half-life of 0.20 hours after intravenous injection. The volume of distribution at steady-state (Vss) after intravenous and intramuscular injection is about 0.16 L/kg (0.42 L/kg for free drug).
Kristen Zeitler et al.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 69(2), 107-115 (2012-01-05)
The pharmacology, safety, efficacy, pharmacokinetics, pharmacodynamics, current place in therapy, and potential future therapeutic uses of inhaled aztreonam are reviewed. Inhaled aztreonam, a newly formulated lysine salt of the original monobactam antibiotic, is approved for the treatment of respiratory symptoms

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门